Viruses · 2026
Respiratory Syncytial Virus-Associated Severe Acute Respiratory Infections in Hospitalized Patients at a University Hospital Center in Rabat, Morocco: An Epidemiological Overview.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El-Amin Ghizlane, Hafidi Naima El, Benchekroun Soumia, Chafiq Mahraoui, Zouaki Amal, Touyar Nora, Bouihat Najat, Kettani Salma Ech-Cherif El, Harrak Saad, Ed-Dafali Larbi, Bentalha Aziza, Alilou Mustapha, Hamzaoui Hamza El, Barkat Amina, Elouardighi Ilham, Dendane Tarek, Abidi Khalid, Ayachi Jihane Bel, Madani Naoufal, Abouqal Redouane, Harmouche Hicham, Maamar Mouna, El Jaoudi Rachid, Feindiri Mourad, Seffar Myriam, Bouskraoui Mohamed, Kabbaj Hakima
Аннотация
UNLABELLED: Respiratory syncytial virus (RSV) imposes a substantial burden of severe acute respiratory infection (SARI), especially in young children and the elderly.
METHODS: We describe RSV epidemiology among hospitalized SARI patients at the Ibn Sina University Hospital Center (Rabat, Morocco) from 1 January 2021, to 31 December 2025, using multiplex PCR (BioFire® RP2.1plus or Xpert® SARS-CoV-2/Flu/RSV).
RESULTS: Among 4604SARI samples, RSV prevalence was 16.1% (739/4604), predominantly pediatric (88.6%, p < 0.001), with peak burden in infants <6 months (70.4% of cases, p < 0.001). Pediatric prevalence was 28.3% (655/2316) vs. 3.8% (84/2204) in adults (p < 0.001), with predominance in the elderly ≥60 years (51/1041, 4.9%). Co-infections occurred in 46.7% (310/665) of FilmArray-tested positives (total = 665), led by rhinovirus/enterovirus (198/310, 63.9%), and were significantly higher in children (48.5%, p < 0.001). RSV peaked in winter (51.6%), except for summer dominance in 2021 (52.5%), reflecting COVID-19 non-pharmaceutical intervention effects.
CONCLUSIONS: These data establish Morocco's first comprehensive RSV surveillance baseline, highlighting post-pandemic epidemiological shifts. As maternal vaccines and monoclonal antibodies emerge, these data inform optimal implementation in low- and middle-income countries (LMICs).
METHODS: We describe RSV epidemiology among hospitalized SARI patients at the Ibn Sina University Hospital Center (Rabat, Morocco) from 1 January 2021, to 31 December 2025, using multiplex PCR (BioFire® RP2.1plus or Xpert® SARS-CoV-2/Flu/RSV).
RESULTS: Among 4604SARI samples, RSV prevalence was 16.1% (739/4604), predominantly pediatric (88.6%, p < 0.001), with peak burden in infants <6 months (70.4% of cases, p < 0.001). Pediatric prevalence was 28.3% (655/2316) vs. 3.8% (84/2204) in adults (p < 0.001), with predominance in the elderly ≥60 years (51/1041, 4.9%). Co-infections occurred in 46.7% (310/665) of FilmArray-tested positives (total = 665), led by rhinovirus/enterovirus (198/310, 63.9%), and were significantly higher in children (48.5%, p < 0.001). RSV peaked in winter (51.6%), except for summer dominance in 2021 (52.5%), reflecting COVID-19 non-pharmaceutical intervention effects.
CONCLUSIONS: These data establish Morocco's first comprehensive RSV surveillance baseline, highlighting post-pandemic epidemiological shifts. As maternal vaccines and monoclonal antibodies emerge, these data inform optimal implementation in low- and middle-income countries (LMICs).